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The inability to associate aversive events with relevant cues (i.e. fear learning) may lead to
maladaptive anxiety. To further study the role of the serotonin transporter (SERT) in fear learning,
classical fear conditioning was studied in SERT knockout rats (SERT/) using fear potentiation of
the startle reﬂex. Next, fear acquisition and concomitant development of contextual conditioned
fear were monitored during training. To differentiate between developmental and direct effects of
reduced SERT functioning, effects of acute and chronic SSRI treatment were studied in adult rats.
Considering the known interactions between serotonin and corticotropin-releasing factor (CRF), we
studied the effect of the CRFR1 antagonist CP154,526 on behavioral changes observed and
determined CRF1 receptor levels in SERT
/ rats. SERT/ showed blunted fear potentiation
and enhanced contextual fear, which resulted from a deﬁcit in fear acquisition. Paroxetine
treatment did not affect acquisition or expression of fear-potentiated startle, suggesting that
disturbed fear learning in SERT/ results from developmental changes and not from reduced SERT
functioning. Although CRF1 receptor levels did not differ signiﬁcantly between genotypes, CP154,526o.2015.07.004
CNP. All rights reserved.
0031691.
(E.Y. Bijlsma).
E.Y. Bijlsma et al.1734treatment normalized both cue- and contextual fear in SERT/ during acquisition, but not
expression of fear-potentiated startle. The disrupted fear acquisition and concomitant increase in
contextual conditioned fear-potentiated startle fear in SERT/ resembles the associative learning
deﬁcit seen in patients with panic disorder and suggests that normal SERT functioning is crucial for
the development of an adequate fear neuro-circuitry. Moreover, the normalization of fear
acquisition by CP154,526 suggests a role for central CRF signaling in the generalization of fear.
& 2015 Elsevier B.V. and ECNP. All rights reserved.1. Introduction
Classical fear conditioning is the process by which a previously
neutral stimulus comes to evoke fear following its repeated
pairing with an aversive unconditioned stimulus. The inability to
learn these fear contingencies results in unpredictability of the
aversive event and consequently in maladaptive fear, reﬂected
in enhanced contextual fear (Baas et al., 2008; Grillon, 2002).
Literature suggests that this type of associative learning deﬁcit
plays a crucial role in the development of several anxiety
disorders, including panic disorder (Lissek et al., 2009). The
serotonin system is involved in fear regulation (Burghardt et al.,
2004; Grillon et al., 2007a). In addition, serotonin has been
implicated in both the pathology and the treatment of panic
disorder. First, selective serotonin re-uptake inhibitors (SSRIs),
acting on the serotonin transporter, are medication of choice for
panic disorders (Andrews and Hunt, 1998; Romano et al., 2004).
Further, panic disorder has been associated with a polymorphism
in the serotonin transporter gene (SLC6A4) (Strug et al., 2010)
increased serotonin turnover (Esler et al., 2007) and both
decreased and increased serotonin transporter availability
(Maron et al., 2004; Maron et al., 2011).
Another important mediator in fear learning is the
neuropeptide corticotropin-releasing factor (CRF). For
example, local repeated administration of CRF into the
basolateral amygdala potentiates the acquisition of cue-
conditioned fear (Bijlsma et al., 2011) and CRF1 receptor
antagonists effectively block the acquisition and expression
of contextual conditioned fear (Hubbard et al., 2007;
Walker et al., 2009).
Several studies suggest direct interactions between ser-
otonin and CRF in the regulation of anxiety-like responses
(Lukkes et al., 2009; Meloni et al., 2008). In addition,
central administration of CRF decreases activity of seroto-
nin neurons in the raphe and serotonin release in forebrain
regions in a dose-dependent manner (Kirby et al., 2000;
Price and Lucki, 2001). Interestingly, a recent study within
our department showed that interactions between serotonin
transporter and CRF1 receptor polymorphisms are asso-
ciated with deﬁcient associative fear learning in healthy
subjects (Heitland et al., 2013). Together, these studies
suggest that especially the interplay between these two
brain systems may be important for adequate fear learning.
This study aimed at further studying the role of the
serotonin transporter in classical fear conditioning deﬁcits
using a SERT knockout (SERT/) model in rats. This SERT/
 rat was created by N-ethyl-N-nitrosurea (ENU)-driven
target-selected mutagenesis resulting in a premature stop
codon (Smits et al., 2006). This premature stop codon
results in a complete ablation of SERT in the SERT/ rat(Homberg et al., 2007a). This SERT/ rat shows selective
disturbances in 5-HT homeostasis, including nine-fold higher
extracellular 5-HT levels in the hippocampus and decreased
intracellular availability of 5-HT (Homberg et al., 2007a).
Behaviorally, the SERT/ rat shows increased anxiety-like
behavior in exploration-driven paradigms (Olivier et al.,
2008), decreased memory performance in an object recog-
nition paradigm (Olivier et al., 2009), but improved inhibi-
tory control (Homberg et al., 2007b). Here we studied
classical fear conditioning in SERT/ rats by measuring
potentiation of the acoustic startle response (i.e. fear-
potentiated startle), a robust measure of defensive states
in both humans and rodents (Bijlsma et al., 2011; Grillon,
2008). Recently, it was reported that panic disorder patients
show an associative fear learning deﬁcit in this fear-
potentiated startle paradigm, resulting fear-like responding
to safety cues (Lissek et al., 2009). To differentiate
between developmental and direct effects of reduced SERT
functioning, the effect of pharmacological SERT inhibition in
adulthood on the acquisition and expression of fear-
potentiated startle were studied following acute and
chronic paroxetine treatment in Wistar rats. In addition,
because of above mentioned interactions between serotonin
and CRF and the putative inhibitory effects of CRFR1
antagonists on contextual conditioned fear, we studied
changes in CRF1 receptor levels in SERT
/ rats and tested
the hypothesis that the CRFR1 antagonist CP154,526 was
able to normalize the fear learning deﬁcits found.2. Experimental procedures
2.1. Subjects
SERT knockout rats (Slc6a4 [1Hubr]) on a Wistar rat genetic back-
ground were generated by ENU-driven mutagenesis (Smits et al.,
2006). All males were derived from crossings between heterozygous
(SERT+/) rats and genotyped as described previously [36]. In
Experiments 1, 2, 4 and 5, SERT+/+, SERT+/ and SERT/ rats
were compared. Rats were housed in groups of four, with mixed
genotype. In Experiment 3, male Wistar rats were used (Harlan,
Zeist, the Netherlands), which were housed in groups of four and
were allowed to acclimate to the facilities for two weeks before the
start of the experiment. All animals were housed in a temperature
(21 1C 72), humidity (55% 75), and light controlled environment
(lights on from 6 a.m. to 6 p.m.). Food and water were freely
available in the home cages. The experiments were carried out
during the light phase of the day–night cycle between 8 a.m. and
4 p.m. This study was approved by the ethical committee of the
Academic Biomedical Center (DEC-ABC), Utrecht University, The
Netherlands.
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Eight startle devices were used simultaneously (SR-lab, San Diego
instruments, San Diego CA, USA). The startle devices consisted of a
Plexiglas cylinder (9 cm diameter and 20 cm length) placed on a
Plexiglas base in a ventilated sound-attenuated cubicle. During the
FPS experiments this startle device was equipped with a stainless steel
grid ﬂoor. Cage movements were measured with a piezoelectric ﬁlm
attached to the Plexiglas base of the startle device. Startle stimuli
(50 ms white-noise bursts) were presented through a piezoelectric
tweeter situated 15 cm from the top of the cylinder. Background noise
was set at 70 dB. Startle amplitudes were sampled each ms during a
period of 65 ms beginning at the onset of the startle stimulus. The
startle response was measured as the maximum peak-to-though wave-
form during the 65 ms period. Each startle device was equipped with a
stimulus light (180 lx) in the ceiling situated 15 cm from the top of the
cylinder for FPS conditioning. There was no background illumination in
any of the experiments.2.3. Expression of fear-potentiated startle
Animals were trained for 2 consecutive days. During both training
sessions, animals were presented with 10 cue-shock pairings
(0.6 mA during the last 500 ms of the 3700 ms light cue) at an
average interval of 4 min (range: 3–5 min). 24 h later, rats were
tested for fear expression using the FPS test. Test procedure was as
follows: After an acclimation period of 5 min, 10 habituation stimuli
were presented (105 dB), followed by 40 startle stimuli (20 100
and 105 dB, ISI 30 s). Half of the 40 startle stimuli were presented
during the last 50 ms of a 3250 ms light cue (cued); the other half
were delivered in darkness (non-cued). Expression of fear-
potentiated startle was analyzed both on basis of absolute startle
values as well as percentage potentiation (percentage fear-
potentiated startle: [(cued – non-cued)/non-cued n 100%].2.4. Fear acquisition
Acquisition of fear-potentiated startle was assessed during an
adjusted training session. To optimally study fear learning, and its
modulation by pharmacological treatment, over the course of
training startle responses to cued and non-cued trials was assessed
during training. To this end, animals were exposed to two startle
stimuli (cued and non-cued, 105 dB) before the ﬁrst cue-shock
pairing and in between the other cue-shock pairings. To visualize
the training effect in Experiment 2, responses from each subject to
cued and non-cued trials during fear acquisition training were
collapsed into three phases: The initial phase (cued and non-cued
response before the ﬁrst cue-shock pairing); ‘1st phase’ (cued and
non-cued response during the ﬁrst set of 5 cue-shock pairings);
and‘2nd phase’ (cued and non-cued response during the second set
of 5 cue-shock pairings).2.5. Drugs
Paroxetine hydrochloride hemi-hydrate (10 and 20 mg/kg, Phar-
macy Mediq, Bergen op Zoom) was dissolved in water and adminis-
tered by daily injections (p.o.) in a volume of 2 ml/kg.
CP154,526 (butyl-ethyl-(2,5-dimethyl-7-(2,4,6-trimethylphenyl)-
7H-pyrrolo(2.3-d)pyrimidin-4-l)amine)-HCl; gift from Servier,
Croissy/Seine France) was suspended in 2% Tween80 in distilled
water and administered intraperitoneally in volume of 2 ml/kg
30 min before FPS training (Experiment 4B, 10 and 30 mg/kg) or
test (experiment 5, 10 mg/kg).2.6. In situ hybridization
CRF 1 receptor mRNA levels in basolateral amygdala (bilateral,
Bregma 2, 30, Paxinos) and dorsal raphe nucleus (Bregma 7, 30,
7, 64, Paxinos) were determined in drug-naive SERT+/+ and
SERT/ rats. Rats were decapitated and brains were removed and
stored at 80 1C until further use. Brains were sliced into coronal
sections, sections were directly placed onto SuperFrost plus slides
(Gerhard Menzel GmbH, Germany) and immediately frozen at
80 1C until further use. For in situ hybridization, the RNAscope
RED 2.0 FFPE assay (Advanced Cell Diagnostics Inc., Hayward, CA)
was performed as described in the user manual (Rev.20121022).
Speciﬁc probes targeted at CRFR1 (NM_030999.3, catalog 318931),
a positive control (housekeeping gene Peptidyl-prolyl cis-trans
isomerase B (PPIB NM_022536), and the bacterial gene dihydrodi-
picolinate reductase (dapB; EF191515) as a negative control were
obtained from Advanced Cell Diagnostics Inc., Hayward, CA (Wang
et al., 2012).
Analyses of expression levels: The slides were analyzed with a
bright-ﬁeld microscope (Olympus, BX50). The pictures were made
with a Leica camera (type DFC320) and the counting was performed
using Image-Pro Plus version 630.0.512 (1993–2008, Media Cyber-
netics, Inc.) for Windows XP/Vista. Expression levels represented by
red dots were manually counted twice for each area by an observer
who was blind for genotype. For the amygdala, four or ﬁve squares
of 8934 mm2 (95.91 mm 93.15 mm), spread over the area, were
counted. For the dorsal RN, three rectangles of 31,244 mm2
(258.75 mm 120.75 mm) were vertically placed under the aquaduct
and counted using the same strategy as for the BLA.
2.7. Overview of experiments
All experiments were carried out in separate experimental groups.
4 days before the start of an experiment, animals were habituated
to the startle set-up during a habituation session (30 startle stimuli
(10 100, 105 and 115 dB, ISI 30 s)). Three intensities were used
during this habituation session in order to capture individual
differences in startle reactivity. In Experiments 2, 3A, and 4 mean
startle amplitude during this habituation session was used to evenly
distribute animals over experimental conditions.
Experiment 1. Expression of fear-potentiated startle was assessed
using different shock intensities during training (0.3 mA vs 0.6 mA).
Based on the results from Experiment 1, all subsequent studies were
performed using a shock intensity of 0.6 mA.
Experiment 2. The level of fear acquisition was assessed during
the ﬁrst FPS training using the fear acquisition training protocol.
Mean startle amplitude during the habituation session was used to
evenly distribute animals over experimental conditions. To control
for general deﬁcits in sensory information processing and to assess
the speciﬁcity of the fear-related deﬁcit, prepulse inhibition and
light-enhanced startle, a measure of sustained anxiety, were
assessed (see Supplement 1).
Experiment 3. To differentiate between developmental and direct
effects of SERT blockade, the effects of acute and chronic (21 days)
paroxetine treatment (0, 10 and 20 mg/kg) on fear acquisition
(A) and expression of FPS (B) were studied in Wistar rats. To assess
the acute effects on fear acquisition, paroxetine was administered
1 h before fear acquisition and effects were analyzed during FPS
expression 24 h later. To assess the chronic effects on fear acquisi-
tion, animals were treated for 21 days, starting one week after the
habituation session. On day 21, animals were trained 1 h after drug
administration and effects were analyzed during FPS expression
24 h later. In Experiment 3A the mean startle amplitude during the
habituation session was used to evenly distribute animals over
treatment conditions. The acute and chronic effects on fear
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Figure 1 The expression of fear-potentiated startle in SERT+/+, SERT+/ and SERT/ rats following fear-potentiated startle training
with 0.3 (A, C) or 0.6 mA (B, D) foot shock. (A and C) shows mean startle amplitude (7SEM) to non-cued and cued trials during fear-
potentiated startle (n=12–17 per genotype for 0.3 mA condition and n=19–20 per genotype for 0.6 mA condition). (B) and (D) shows
percent fear-potentiated startle (mean7SEM). *Po0.05 for cued versus non-cued trials. Po0.05 compared to SERT+/+.
E.Y. Bijlsma et al.1736expression were studied in pre-trained rats. Animals were trained
for two consecutive days and tested for baseline FPS 24 h later.
Animals were assigned to treatment groups on basis of their
baseline FPS response. A week later, animals were exposed to
another training session and 24 h later drug treatment started.
Animals were treated for 21 days and on day 1 (acute) and day 21
(chronic) animals were tested for FPS 1 h after drug administration.
Animals did not receive additional training during the treatment
period to prevent possible interference of drug treatment with
further acquisition.Experiment 4. To adequately assess potential differences in the
development of contextual conditioned fear between genotypes, an
additional control group was included (Experiment 4A). Standardly
trained vehicle groups (cue-shock group) were compared to vehicle
control groups that were not shocked during fear acquisition (cue-
no-shock group). In addition, we studied whether the blunted FPS in
SERT/ rats could be normalized by CRF1 receptor blockade
during fear acquisition (Experiment 4B). To this end, the CRF1
receptor antagonist CP154,526 was administered once, 30 min
before fear acquisition and effects were analyzed during FPS
expression 24 h later. The mean startle amplitude during habitua-
tion was used to evenly distribute animals over experimental
groups.Experiment 5. The effect of CP154,526 (10 mg/kg versus vehicle)
on expression of FPS in pre-trained rats was studied in a within-
subject design. A cue-no-shock control group was included to
differentiate between drug effects on contextual fear and baseline
startle reactivity. Assignment of animals to the cue-shock and cue-
no-shock condition was based on mean startle amplitude during the
habituation session. Pre-trained animals were tested twice, with a
one-week interval. In both test weeks, animals were trained once
and 24 h later, administered with CP154,526 or vehicle and tested
for FPS expression. Treatment was counterbalanced over the two
test sessions.
Experiment 6. To evaluate whether the disrupted fear acquisition
in SERT/ directly results from changes in CRFR1 expression, we
studied CRFR1 mRNA expression in the basolateral amygdala and
dorsal raphe nucleus of SERT/ and SERT+/+ rats using in situ
hybridization.
2.8. Data analyses
All data were analyzed using repeated measures ANOVAs with
stimulus intensity and trial type (cued versus non-cued) as within-
subject factors. Speciﬁc additional contrasts per experiment:
Experiments 1, 2, 4 and 5: genotype as between-subjects factor;
Experiment 1: shock intensity as between-subjects factor;
1737Reversal by blockade of CRF1 receptorsExperiment 2: phase as within-subject factor; Experiment 4A and 4:
condition (cue-no-shock group and cue-shock group) as between-
subjects factor; Experiment 3 and 4B: drug (three levels) as a
between-subjects factor. In Experiment 5, drug (2 levels) was added
as a within-subject factor. For analyses of CRF1 receptor mRNA
expression in Experiment 6, expression levels were calculated by
correcting the counted amount of dots for the total area. Mean
expression levels for the BLA were analyzed using repeated
measured ANOVA with hemisphere as within-subject factor and
genotype as between-subject factor. Two animals were excluded
from analysis due to damage to the sections. Mean expression levels
for the dorsal raphe nucleus were analyzed using independent
students t-test. P-values of 0.05 or smaller were considered
signiﬁcant. For complete statistical reports, see Tables 1 to 4 in
Supplement 2.3. Results
Experiment 1: SERT/ rats show no fear-potentiated
startle.
With both shock intensities, genotypes differed in their
response to cued and non-cued trials (trial genotype interac-
tion: [F2,42=4.9, po0.05 and F2,52=8.9, po0.001 for 0.3 and
0.6 mA respectively]): SERT+/+ and SERT+/ showed signiﬁcant
potentiation of the startle response whereas SERT/ did not
(SERT+/+: F1,11=12.4, po0.01, SERT+/: F1,15=18.6, p=0.001,
SERT/: F1,16=1.2, NS; Figure 1A and B). The response to non-
cued trials was increased in SERT/ following 0.6 mA, but not
0.3 mA FPS training. However, this effect did not reach signiﬁ-
cance (effect genotype on non-cued trials [F2,42o1] and
[F2,52=2.8, po0.1] for 0.3 and 0.6 mA respectively). The blunted
FPS response in SERT/ under both shock intensities was also
reﬂected in a signiﬁcantly lower percentage FPS (Effect of
genotype [F2,42=6.5, po0.01] and [F2,52=4.4, po0.05] for
0.3 and 0.6 mA respectively, Figure 1C and D).
Experiment 2: Blunted fear-potentiated startle due to
deﬁcient fear acquisition.
SERT+/+ and SERT+/ showed signiﬁcant acquisition of the
cue-shock association, whereas SERT/ did not (trial
genotype interaction: F2,50=3.3, po0.05; effect of trial:
SERT+/+ F1,17=10.1, po0.01; SERT+/ F1,18=5.0, po0.05;
and SERT/ F1,15o1, Figure 2A and C). In addition, whereas
SERT+/+ differentiated between cued and non-cued trialsSERT
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Figure 2 Acquisition of cue-conditioned fear during fear-potentia
and SERT/ (C, n=17) rats. ‘Initial’ represents startle amplitude
cue-shock pairing. ‘1st phase’ represents mean startle amplitude
between the ﬁrst set of 5 cue-shock pairings. ‘2nd phase’ represen
cued trials presented in between the second set of 5 cue-shock paduring both the ﬁrst and second phase of acquisition (1st phase
[T1,17=2.6, po0.05], 2nd phase [T1,17=3.0, po0.01]),
SERT+/ only differentiated between cued and non-cued trials
during the ﬁrst phase of acquisition (1st phase [T1.18=2.9,
po0.001], 2nd phase T1,18=1.7, NS]). The response to non-
cued trials increased over time independently of genotype
[phase genotype interaction and overall effect phase on non-
cued trials F4,106o1 and F2,106=36.6, po0.001].
Experiment 3: Neither acute nor chronic pharmacological
SERT inhibition affects the acquisition and expression of
fear-potentiated startle.
Acquisition: Following fear acquisition signiﬁcant FPS was
induced (Effect of trial [F1,30=39.3, po0.001] and
[F1.32=32.0, po0.001] in acute and chronic group respec-
tively) and neither acute nor chronic paroxetine treatment
signiﬁcantly affected the level of fear acquisition, as
measured 24 h later ([drug trial interaction F1,30o1 and
F2,32o1 in acute and chronic group respectively]; Figure 3A
and C). Rather, acute paroxetine treatment during acquisi-
tion increased overall startle responding 24 h later [main
effect dose F1,30=3.6, po0.05], an effect that was primar-
ily mediated by the 10 mg/kg dose [p=0.053].
Expression: Neither acute nor chronic paroxetine treat-
ment affected the expression of FPS in pre-trained rats
(trial dose interaction F2,30o1 for both time points;
Figure 3B and D). Signiﬁcant FPS was established at both
time points measured (Effect of trial [F1,30=19.0, po0.001]
and [F1,30=21.6, po0.001] for acute and chronic treatment
respectively).
Experiment 4A: SERT/ rats show exacerbated contex-
tual conditioned fear in the fear-potentiated startle
paradigm.
The level of contextual conditioned fear was measured
during non-cued trials. Separate analyses of non-cued trials
in cue-no-shock and cue-shock groups showed that the level
of contextual conditioned fear differed between genotypes
[condition genotype interaction F2,66=5.1, po0.01]. More
speciﬁcally, SERT/ and SERT+/ in the cue-shock group
showed clear contextual conditioned fear, which was
reﬂected in a signiﬁcant increase in response to non-cued
trials compared to the cue-no-shock group ([F1,21=12.9,
po0.01] and [F1,23=7.7, po0.05] in SERT/ and SERT+/
respectively, Figure 4B and C). SERT+/+ rats, on the otherSERT-/-
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Figure 3 The effect of acute and chronic treatment with paroxetine on the acquisition (A, C) and expression (B, D) of fear-
potentiated startle (n=11–12 per experimental group). Data is presented in absolute startle values (mean7SEM) during non-cued
and cued trials. *po0.05 for cued versus non-cued trials. po0.05 compared to vehicle. In all 4 experiments, signiﬁcant difference
between cued and non-cued trials was induced. These signiﬁcant effects are not depicted in the graphs.
E.Y. Bijlsma et al.1738hand, did not show contextual conditioned fear ([F1,21=1.5,
NS], Figure 4A). Direct comparison of the three genotypes in
the cue-shock group showed that SERT/ rats showed
exacerbated contextual conditioned fear during non-cued
trials compared to SERT+/+, whereas SERT+/ did not
(effect of genotype [F2,33=10.5, p=0.001]; post-hoc ana-
lyses SERT/ vs SERT+/+ [p=0.001], SERT+/ vs SERT+/+
[p=0.953]).
Furthermore, overall analyses of the FPS response in all
genotypes conﬁrmed the previously found disturbance in
FPS in SERT/ rats [condition genotype trial interac-
tion: F2,66=3.7, po0.05]. Both SERT+/+ and SERT+/ in
the cue-shock group showed a signiﬁcant increase in
response to cued trials relative to cue-no-shock group
(trial condition interaction [F2,12=8.0, p=0.01] and
[F1,23=9.7, po0.01] in SERT+/+ and SERT+/ respec-
tively). These genotypes also clearly differentiated between
cued and non-cued trials, reﬂecting normal FPS. On the
other hand, SERT/ rats in the cue-shock group showed an
overall increase in startle reactivity relative to the cue-no-
shock control group (trial condition interaction [F1,21o1]
and overall effect of condition [F1,21=13.5, p=0.001]). In
addition, these SERT/ in the cue-shock group did not
differentiate between cued and non-cued trials.Experiment 4B: CP154,526 during fear acquisition nor-
malizes fear-potentiated startle and prevents exacerbation
of contextual conditioned fear in SERT/ rats.
As genotypes differed markedly in basal fear acquisition,
drug effects could differ strongly between genotypes. There-
fore, all effects in this experiment were analyzed separately
for each genotype. In SERT+/+ and SERT+/, administration of
CP154,526 during acquisition had no effect on fear expression
24 h later, nor on the startle response per se (SERT+/+:
[drug trial interaction F2,32o1, overall effect of drug
F2,32o1]; SERT+/: [drug trial interaction F2,37o1, overall
effect of dose F2,37=1.1, NS]; Figure 4D and E, respectively). In
SERT/, on the other hand, CP154,526 treatment during
acquisition had a differential effect on cued and non-cued
trials ([drug trial interaction F2,33=3.8, po0.05]; Figure 4F).
Administration of 10 mg/kg CP154,526 during acquisition
resulted in a signiﬁcant potentiation of the startle response
in response to cued trials (effect trial: [T11, po0.01]), whereas
the response to cued and non-cued trials was similar following
treatment with vehicle or 30 mg/kg CP154,526 (effect trial:
vehicle [T10=0.3, NS]; 30 mg/kg [T12=0.2, NS]). This sig-
niﬁcant fear potentiation following 10 mg/kg CP154,526
in SERT/ was reﬂected in the absolute difference scores,
as these scores were signiﬁcantly increased compared to
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Figure 4 Effect of CP154,526 during acquisition on expression of fear-potentiated startle in SERT+/+, SERT+/ and SERT/ rats
(n=11–15 per experimental group). Data is presented in absolute startle values (mean7SEM) during non-cued and cued trials. (A–C)
represent the effect of fear acquisition on expression of fear-potentiated startle in the cue-shock condition compared to the no-shock
control condition in SERT+/+, SERT+/ and SERT/ rats, respectively. (D–F) represent the effect of acute CP154,526 administration
before acquisition on the expression of fear-potentiated startle 24 h later in SERT+/+, SERT+/ and SERT/ rats, respectively (inset in
(F) difference score between cued and non-cued trials). *po0.05 for cued versus non-cued trials; po0.05 compared to no-shock control
group; §po0.05 compared to vehicle control; &po0.05 compared to non-cued trials of cue-no-shock control group.
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Figure 5 Effect of CP154,526 on expression of fear-potentiated startle in pre-trained SERT+/+ (A), SERT+/ (B) and SERT/ (C) rats
(n=7–9 per genotype for cue-no-shock control groups and n=9–10 per genotype for cue-shock groups). CP154,526 was administered 30 min
before the fear-potentiated startle test. Data is presented in absolute startle values (mean7SEM) during non-cued and cued trials.
*po0.05 for cued versus non-cued trials. Effect of CP154,526 on overall startle reactivity is not depicted in (A, C).
1739Reversal by blockade of CRF1 receptorsSERT/ vehicle controls (Effect of drug [F2,33=3.8, po0.05];
post-hoc analyses: 10 mg/kg vs vehicle [p=0.033], 30 mg/kg vs
vehicle [p=0.913], inset Figure 4F), whereas they were
unaltered in SERT+/+ and SERT+/ rats [effect of drug
F2,32o1 and F2,37o1 respectively]. In addition, in SERT/,
a main effect of CP154,526 on overall startle responding
revealed that CP154,526 administration during acquisition also
prevented the development of contextual conditioned fear, as
measured 24 h later (main effect drug [F2,33=4.6, po0.05]).
This effect was primarily due to the 30 mg/kg dose.Experiment 5: CP154,526 does not affect expression of
fear-potentiated startle.
CP154,526 had no speciﬁc effect on the level of fear
potentiation when administered before the fear-potentiated
startle test in pre-trained rats, rather it signiﬁcantly decreased
the overall startle response (main effect drug [F1,47=21.5,
po0.001], dose condition trial interaction [F1,47o1]);
Figure 5). This effect tended to be stronger in the cue-shock
group, compared to the cue-no-shock group (drug condition
interaction [F1,47=3.86, p=0.055]). The genotype differences
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Figure 6 CRF1 receptor mRNA expression level in the basolateral amygdala (A, n=9 for both genotypes) and dorsal raphe nucleus
(B, n=10 for both genotypes) of SERT+/+ and SERT/ rats. *po0.05 compared to SERT+/+.
E.Y. Bijlsma et al.1740in expression of FPS, as detected earlier, were conﬁrmed
(trial genotype interaction in cue-shock group [F2,25=10.0,
p=0.001]; effect trial in SERT+/+ [F1,9=18.2, po0.01],
SERT+/ [F1,8=19.0, po0.01] and SERT/ {F1,8=1.4, NS]).
In the cue-no-shock control group, on the other hand, no fear
potentiation was present and genotypes did not differ in startle
reactivity (effect of trial [F1,22o1], effect of genotype
[F2,22o1], genotype trial interaction [F2,22=2.7, po0.1]).
Experiment 6: CRF1 receptor mRNA expression in BLA and
DR was not signiﬁcantly altered in SERT/ rats.
CRF1 receptor levels in the basolateral amygdala, repre-
sented by number of dots, were not signiﬁcantly different
between SERT+/+ and SERT/ rats (main effect genotype
[F1,16=1.3, NS], Figure 6A). Because of a trend towards a
difference between hemispheres (main effect hemisphere
[F1,16=4.1, po0.1], genotypehemisphere interaction
[F1,16=3.4, po0.1]), genotype effects were also analyzed in
both hemispheres separately. This analysis showed a signiﬁcant
decrease in CRF1 receptor levels in the left BLA of SERT
/
rats (t16=2.468, po0.05), whereas CRF1 receptor levels in
the right BLA did not differ between genotypes (t16=0,116,
NS). No signiﬁcant differences CRF1 receptor levels in the
dorsal raphe nucleus were found between SERT+/+ and
SERT/ rats ([t18=0.125, NS], Figure 6B).4. Discussion
This study evaluated the role of SERT in classical fear
conditioning using a SERT knockout rat model. We found a
clear disruption of cue-conditioned fear in SERT/ rats, as
measured with the fear-potentiated startle. This disruption
was due to a deﬁcit in fear acquisition and was accompanied
by development of enhanced contextual conditioned fear.
Neither the acquisition nor the expression of fear-potentiated
startle was affected by pharmacological SERT inhibition. More-
over, both the deﬁcit in acquisition of cue-conditioned fear and
the development of exacerbated contextual conditioned fear
in SERT/ rats could be reversed by treatment with the CRF1
receptor antagonist CP154,526 during acquisition.
The failure to learn the cue-shock contingency resulted
in increased contextual fear in SERT/ rats. This wasspeciﬁcally related to the fear learning deﬁcit, as SERT/
rats show normal unconditioned anxiety in the light-
enhanced startle paradigm (Supplement 1). Furthermore,
it is unlikely that the fear learning deﬁcit is a result of
increased contextual fear, because results from Experiment
4 show that the prevention of contextual fear by 30 mg/kg
CP-154,526 did not result in reinstatement of the cued fear
expression. In humans, unawareness of the cue-shock con-
tingency also increases contextual fear (Baas et al., 2008), a
phenomenon that is speciﬁcally associated with maladap-
tive fear processing in panic disorders patients (Grillon
et al., 2007b; Lissek et al., 2009). Interestingly, these
patients shown normal startle responding in unconditioned
measures of fear and anxiety (Grillon et al., 1994; Melzig
et al., 2007). Thus, the current ﬁndings in SERT/ rats ﬁt
well with aforementioned human data and resemble both
fear- and anxiety-related potentiated startle data in panic
disorder patients. Interestingly, several studies indicate
altered SERT functioning in panic disorder (Esler et al.,
2007; Strug et al., 2010), further strengthening the link
between SERT availability and fear learning deﬁcits in
anxiety disorders.
To the best of our knowledge, this is the ﬁrst report on
the effect of chronic SSRI treatment on the acquisition and
expression of fear-potentiated startle in rodents. The lack
of effect on expression of cued fear is in line with the single
human fear-potentiated startle study available (Grillon
et al., 2009). The ﬁnding that neither acute nor chronic
paroxetine treatment affected the acquisition and expres-
sion of cued conditioned fear suggests that the fear learning
deﬁcit found in SERT/ is due to developmental changes
and does not result from compromised SERT functioning
during fear learning. Serotonin is known to modulate
neurodevelopment (Gaspar et al., 2003; Lauder, 1990) and
the neural systems regulating anxiety-like behavior are
especially sensitive to changes in serotonergic functioning
during early development (Gross et al., 2002; Vinkers et al.,
2010). It has already been reported that SERT/ mice
show increased spine density and excitatory drive of the BLA
(Wellman et al., 2007). Such changes in neuronal structure
and excitability may also be responsible for the learning
deﬁcit observed in SERT/ rats. However, the exact
1741Reversal by blockade of CRF1 receptorsmechanism underlying this deﬁcit in SERT/ rats is subject
of further investigation.
Interestingly, acute administration of paroxetine during
fear acquisition did increase overall startle responding 24 h
later, which suggests that acute SERT inhibition potentiates
the acquisition of contextual conditioned fear. To the best
of our knowledge, this is the ﬁrst time the acute anxiogenic
effect of SSRIs in humans, as measured with fear-
potentiated startle, is shown in rodents (Burghardt et al.,
2004; Grillon et al., 2007a). Together with ﬁndings from our
concurrent study in humans that SERT S/S carriers show
exaggerated contextual fear learning (Heitland et al.,
2013), these results suggest that increased extracellular
serotonin levels may also be responsible for the increased
contextual conditioned fear seen in SERT/ rats.
Findings from the present study indicate that CRF1 receptors
are especially important in fear acquisition. CP154,526 given
before acquisition training, at least partly, reinstated the fear-
potentiated startle response and blocked the development of
contextual conditioned fear in SERT/ rats. CP154,526
administered to pre-trained rats however, neither normalized
the expression of fear-potentiated startle nor blocked contex-
tual conditioned fear in SERT/ rats. This absence of effect of
CP154,526 on fear expression in pre-trained rats is consistent
with accumulating evidence that CRF1 receptor antagonists do
not affect the expression of fear-potentiated startle (de Jongh
et al., 2003; Walker et al., 2009). In addition, together with the
ﬁndings from our concurrent study in humans that interactions
between SERT and the CRF1 receptor play a pivotal role in the
regulation of conditioned fear acquisition in healthy subjects
(Heitland et al., 2013), this study not only supports the idea
that especially the interplay between the CRF and serotonin
systems regulates fear learning, but also emphasizes the
translational value of the fear-potentiated startle paradigm.
A putative locus for both the basal deﬁcits in cued fear
learning as well as its normalization by CP154,526 may be the
serotonergic projections originating from the dorsal raphe
nucleus that innervate several brain areas implicated in fear
learning, including the central amygdala and hippocampus. CRF
modulates serotonin release in the raphe (De Souza, 1995; Kirby
et al., 2000; Van Pett et al., 2000) and SERT/ rats show
continuous high serotonergic tone in serotonergic projections
(Homberg et al., 2007a). The current study did not show any
changes in CRF1 receptor expression in the dorsal raphe. This
suggests that altered CRF1 receptor signaling within this area
does not underlie the fear learning deﬁcit found in SERT/
rats. Because this study looked into the anterior part of the DR,
it can not be excluded that changes in CRF1 receptor expression
occurred in the more posterior regions of the DR that have been
implicated in fear regulation as well. However, several studies
have suggested that CRF-serotonin interactions in these poster-
ior regions are selectively mediated by CRF2, and not CRF1,
receptors (for review, see Fox and Lowry (2013)).
Other possible loci for the deﬁcits in cued fear learning and
normalizing effects of CP-154,526 may be the basolateral
amygdala (BLA) and hippocampus. Both brain areas have been
implicated in fear conditioning (Malin and McGaugh, 2006;
Phillips and LeDoux, 1992) and receive strong serotonergic input
from the dorsal raphe (Hensler, 2006). In addition, SERT/ rats
show increased activation of the BLA (Nonkes et al., 2010) and
in mice, lifelong disturbance of SERT functioning is associatedwith increased contextual conditioned fear, increased spine
density within, and excitatory drive of the BLA (Kalueff et al.,
2010; Wellman et al., 2007). Moreover, CRF1 receptor blockade
in both the BLA and hippocampus prevents the development of
contextual conditioned fear (Hubbard et al., 2007; Roozendaal
et al., 2002; Roozendaal et al., 2008), whereas CRF1 receptor
activation within the hippocampus enhances fear learning (Blank
et al., 2003; Radulovic et al., 1999). Chronic activation of the
CRF system within the BLA has also been associated with
increased excitatory drive within this region (Rainnie et al.,
2004). Decreased CRF1 receptor expression in the left BLA, as
observed within the current study, may be indicative of adaptive
changes in response to chronic CRF1 receptor activation and may
suggest that lifelong disruption of SERT functioning mediates
part of its effects via local changes in CRF signaling. In addition,
blockade of CRF1 receptors by CP154,526 may have resulted in
the reinstatement of adequate fear learning in SERT/ rats by
inhibiting the excitatory drive of BLA neurons in SERT/ rats.
In line with this hypothesis, it has already been shown that
repeated activation of CRF receptors in the BLA potentiated the
acquisition of fear-potentiated startle (Bijlsma et al., 2011) and
CRF1 receptor blockade in the BLA prevents the development of
contextual conditioned fear (Roozendaal et al., 2002;
Roozendaal et al., 2008). The relevance of the hemispheric
differences in CRF1 receptor expression found is currently
unknown. Although human research has implicated hemispheric
differences in activation patterns in the regulation of emotion,
few animal studies have investigated lateralized amygdala
involvement and ﬁndings are inconsistent (Adamec and
Morgan, 1994; Baker and Kim, 2004).
Heterozygous SERT knockout showed an intermediate level
of FPS in Experiment 1, but normal FPS in Experiments 4 and 5.
Apparently, high redundancy exists in the involvement of SERT
in normal fear acquisition, as availability of only 60% of normal
SERT levels (Homberg et al., 2007a) is still sufﬁcient to show
relatively normal fear learning.
The deﬁcit in fear acquisition in SERT/ rats is very
consistent, as it was replicated in all separate experimental
groups throughout the study. In addition, it is unlikely that the
absence of fear-potentiated startle in SERT/ rats was due to
a ceiling effect because fear-potentiated startle was also
absent under experimental conditions were SERT/ did not
show exacerbated contextual fear and overall startle levels
were still at baseline levels (Figures 1B and 2). The ﬁnding that
prepulse inhibition (Supplement 1), a measure of sensorimotor
gating, is intact shows that the deﬁcits found are not due to
general deﬁcits in information processing, rather they seem
speciﬁc for the responses to threatening stimuli.
In conclusion, we showed that deletion of the SERT results
in a marked fear learning deﬁcit, which shows similarity to
associative fear learning deﬁcits in panic disorder patients.
These ﬁndings further implicate the serotonin transporter in
the fear learning deﬁcits seen in panic disorder patients.
The ﬁnding that CRF1 receptor blockade during fear acquisi-
tion could normalize fear learning and prevented the
exacerbation of contextual fear, suggests a speciﬁc role
for central CRF signaling and CRF-serotonin interactions in
fear learning. As such, current ﬁndings suggest that the
CRF1 receptor may be an interesting pharmacological target
to prevent fear generalization and subsequent symptom
exacerbation in panic disorder patients.
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